 | ||||||||||||||||
|
This trial is the final important step in determining whether minocycline improves the course of ALS. Minocycline has been tested and been shown to protect nerve cells in many scientific experiments. It reduces cell death and prolongs survival in animal models of ALS, stroke, trauma, Huntington’s disease, and Parkinson’s disease. It has been shown to be beneficial in multiple different animal experiments of ALS, conducted in Europe, Canada and the United States. At study completion, the minocycline trial will be one of the largest investigator-initiated clinical trials conducted to date in ALS; it will provide data not only on the effectiveness of the treatment, but also on the course of ALS. The trial is one of only 3 NIH-funded clinical trials for ALS in the United States. It has several innovative aspects including use of a medication with extensive preclinical testing, a large simple trial design, and sound statistical planning to ensure valid data. Our research, and future patients with ALS, will benefit from your participation. The principal investigator for this study is Paul H. Gordon, MD. In addition to being the Coordinating Clinical Trial Center for the 30 participating sites of the Minocycline trial, we will also be enrolling patients into the study. Please contact Kate Bednarz: keb2114@columbia.edu and phone number (212) 305-2027. Clinical Trials at our Center
|
|||||||||||||||
